Published human studies
A systematic review published in 2026 (Poolton et al.) searched the literature up to 1 June 2026 and found only three studies of BPC-157 in humans [1]:
- A retrospective review of intra-articular injections for knee pain (16 people).
- A retrospective pilot study of intravesical use for interstitial cystitis (12 people).
- A prospective pilot study of intravenous safety (2 people).
The review reports that the studies described no treatment-related adverse events, but rates all of them as poor quality with very low certainty of evidence, and concludes that BPC-157 should not be used clinically in humans outside approved, high-quality trials. The two-person pilot (Lee and Burgess, 2025) reported no side effects; a study that small cannot establish safety [1][2].
What FDA has said
FDA’s page on bulk substances that may present significant safety risks in compounding says of BPC-157: it may pose a risk of immunogenicity for certain routes; peptide-related impurities and characterisation of the active ingredient may be complex; there is no or only limited safety information for the proposed routes, and the agency lacks sufficient information to know whether it would cause harm in humans [5].
In the page’s version of 22 April 2026, BPC-157 appears in the table of substances whose nominations were withdrawn by the nominators. That is not an approval; there is no FDA-approved BPC-157 medicine [5].
What this means for side-effect tracking
For an approved medicine, the label says which side effects are expected and which symptoms need urgent attention. For BPC-157 there is no such list, and the content and purity of unapproved products are not verified. A 2026 sports-medicine review (Mendias et al.) notes that rigorous human safety data for such peptides are scarce and that there is potential for serious harm [4].
PepLabo does not recommend, sell or endorse this substance. It is a tracking app: it records what you tell it and does not tell you what to take.
When to get help
| Sign | Who to contact | How fast | Source |
|---|---|---|---|
| Swelling of the lips, tongue, face or throat, struggling to breathe or swallow, or fainting | Emergency services: anaphylaxis needs medical attention right away. | Emergency | MedlinePlus [6] |
| Painful, red, tender or swollen skin at an injection site, especially with fever or chills | A doctor, the same day (signs MedlinePlus lists for a skin infection). | Today | MedlinePlus [7] |
| Any new symptom that worries you after using BPC-157 | A doctor. Bring the product and anything written on it: there is no label that lists expected side effects. | Today | FDA: no or limited safety information [5] |
| Mild symptoms you are keeping track of | Your doctor at your next appointment; a dated log helps. | At your next appointment | FDA: no or limited safety information [5] |
